Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas

Objective Even without contrast enhancement on MRI scans gliomas can show histological features of anaplasia. These tumors are heterogeneous regarding anaplastic and non-anaplastic areas. Increased amino acid uptake was shown to be associated with dismal prognosis in gliomas. We investigated histological correlates of tumor grading in biopsies obtained from regions with maximum amino acid uptake revealed by F-18-fluoro-ethyl-tyrosin positron emission tomography (FET-PET). Methods We included 22 patients with non-contrast enhancing lesions on MRI scans. PET was performed 10 min after FET injection, and the area of maximum FET uptake was chosen as the biopsy target. In 13 patients neuronavigated biopsies were obtained during tumor resection. Nine patients had a stereotactic biopsy. The ratio of maximum standardized uptake value (SUV) to background was calculated. Histological specimens were classified and graded according to world health organization (WHO) criteria. We investigated cell and vascular density, mitotic activity, proliferation index, microvascular proliferation, nuclear pleomorphism, necrosis and immunoreactivity of LAT1 (SLC7A5), an amino acid transporter with prognostic impact in gliomas. Results 12 of the 22 non-contrast enhancing gliomas corresponded to anaplastic astrocytomas WHO grade III. Vascular and cellular density was correlated highly to the SUV ratio (P = 0.0015 and P = 0.0021, respectively), but with no nuclear pleomorphism, mitotic activity, Mib-1 immunoreactivity, or microvascular proliferation. Thus, no correlation was found between FET uptake and tumor grade. Conclusion FET-PET correlates with vascular and cell density in non-contrast enhancing gliomas. Although tumor grade cannot be predicted, clinical use of FET PET as an indicator for neovascularization should be addressed in future studies.

[1]  J. Saver,et al.  A Quantitative Study , 2005 .

[2]  H. Nawashiro,et al.  L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors , 2006, International journal of cancer.

[3]  L D Lunsford,et al.  Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. , 1993, Journal of neurosurgery.

[4]  W. Koch,et al.  Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. , 2006, Nuclear medicine and biology.

[6]  W. Paulus,et al.  Intratumoral histologic heterogeneity of gliomas. A quantitative study , 1989, Cancer.

[7]  Wolfgang A. Weber,et al.  O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.

[8]  Karl Herholz,et al.  Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  C. Götz,et al.  Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  G. Fuller,et al.  The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. , 1998, Surgical neurology.

[11]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.

[12]  J. M. Ollinger,et al.  Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.

[13]  H. Engler,et al.  Positron emission tomography 11C‐methionine and survival in patients with low‐grade gliomas , 2001 .

[14]  R. Goldbrunner,et al.  O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  H. Engler,et al.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. , 2001, Cancer.

[16]  A. Thiel,et al.  11C-methionine PET for differential diagnosis of low-grade gliomas , 1998, Neurology.

[17]  T. Hölzer,et al.  The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using f-18-fluorodeoxyglucose and c-11-L-methylmethionine. , 1997, Neurosurgery.

[18]  S. Stiver Angiogenesis and its role in the behavior of astrocytic brain tumors. , 2004, Frontiers in bioscience : a journal and virtual library.

[19]  Jörg-Christian Tonn,et al.  Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  K. Plate,et al.  Angiogenesis in malignant gliomas , 1995, Glia.

[21]  I. Fichtner,et al.  The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo , 2006, Clinical Cancer Research.

[22]  F Shishido,et al.  Cerebral glioma: evaluation with methionine PET. , 1993, Radiology.

[23]  G. Reifenberger,et al.  Prognostic Value of O-(2-18F-Fluoroethyl)-l-Tyrosine PET and MRI in Low-Grade Glioma , 2007, Journal of Nuclear Medicine.

[24]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[25]  K. Hamacher,et al.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  C. Marras,et al.  CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients , 2005, Journal of Neuro-Oncology.

[27]  W. Remmele,et al.  Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer , 2004, Virchows Archiv A.

[28]  O. Witte,et al.  Positron emission tomography with injection of methionine as a prognostic factor in glioma. , 2001, Journal of neurosurgery.

[29]  Hong Wang,et al.  Platelet‐derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Alexander Muacevic,et al.  Accuracy and clinical applicability of a passive marker based frameless neuronavigation system , 2000, Journal of Clinical Neuroscience.

[31]  S. Coca,et al.  Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas. , 2000, Surgical neurology.

[32]  J. Rock,et al.  Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. , 1998, Journal of neurosurgery.

[33]  B. Weber,et al.  Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis , 2007, Journal of Nuclear Medicine.

[34]  W. K. Alfred Yung PATHOLOGY AND GENETICS OF TUMOURS OF THE NERVOUS SYSTEM , 2002 .

[35]  P. Courtheoux,et al.  The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. , 1997, Neurosurgery.

[36]  Susan M. Chang,et al.  Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors , 1997, Cancer.